Abstract
Continued development of existing drugs ('drug rediscovery') may offer new therapeutic options and be cost-effective. Rediscovered drugs are commonly prescribed off-label, although licensing can be important to allow safe and controlled prescription of the drugs to patients. Licensing of a new indication for a generic drug, however, is a complicated process since there is no blueprint for this and there is little interest from the pharmaceutical industry due to an unattractive cost-recovery model. In this article, we illustrate the successful license-extension for thioguanine - initially developed in 1950 for leukaemia - as a new treatment for patients with inflammatory bowel disease.
Translated title of the contribution | Continued development of drugs: the path of thioguanine |
---|---|
Original language | Dutch |
Pages (from-to) | D1757 |
Journal | Nederlands Tijdschrift voor Geneeskunde |
Volume | 162 |
Issue number | 0 |
Publication status | Published - 2018 |
Keywords
- English Abstract
- Journal Article